DEVELOPMENT OF ANTICERAMIDE TREATMENT AS A NOVEL MEDICAL COUNTERMEASURE FOR ACUTE EFFECTS OF RADIATION EXPOSURE

Ceramedix Holding, Llc, New York NY

Investigators

Abstract

Ceramedix is developing CX-01, a promising radiation medical countermeasure (MCM), that addresses radiation-induced microvascular (endothelial) injury that leads to subsequent GI organ failure and death. CX-01 inhibits the initiating event of radiation injury and microvascular endothelial apoptosis. Currently, there are no FDA-approved treatments for gastrointestinal acute radiation syndrome (GI-ARS) The complexity of the biological responses to escalating radiation exposures has led to continued development of animal research platforms for reliably modeling different stages of ionizing radiation (IR) induced injury with tactical application to testing novel MCMs.